Gartner® Predicts Augmented Analytics Will Have a Major Impact on Life Sciences Commercial Functions
Gartner® recognizes WhizAI as a Sample Vendor for Augmented Analytics, an emerging technology poised to revolutionize how commercial teams use data insights to optimize outcomes.
Gartner points out that life sciences organizations have reached a turning point. Moving forward, commercial teams must expand and adapt their capabilities to accommodate healthcare providers' expectations for personalized experiences and digital information delivery. Life sciences companies must also equip their market access and patient engagement teams to deliver value and improve patient outcomes. Each of these objectives depends on data-driven decision-making.
Augmented analytics, which Gartner® categorizes on its 2023 Hype Cycle™ as an emerging technology, is crucial in enabling commercial teams to reach those goals.
Download this report to learn about:
- Benefits of augmented analytics for the life sciences commercial function
- Where augmented analytics is on the 2023 life sciences commercial function Hype Cycle™
- How WhizAI is already providing value to its customers today
Contact us to learn more.
Download your E-Book
Download your Whitepaper
People also viewed
Customer Centricity and Digital Experiences which are Redefining Pharma
It is no secret that the pharmaceutical industry has historically flourished from blockbuster products with substantial brand equity, favorable pricing
Awash in Data, Yet Starving for Insights? Transform Life Sciences Commercial Teams with Augmented Analytics
Personalized communication is something the HCPs have come to expect. To do that, pharma sales reps need to know their customers well. In order to know the customer well, they need data. Enterprise pharma companies, however, have many data resources and lots of data at their disposal. In fact, there is a data explosion. So what do you do?
Readiness of Augmented Analytics for Life Sciences Commercial Teams
Demand for smart, agile, and near-instant commercial analytics in Pharma is rising. More contextual, continuous, and connected data and analytics are required to respond to more complex and uncertain business decisions.
Adding Up Data Analytics Total Cost of Ownership (TCO) and How to Lower It
High data analytics expenditures don’t have to be a cost of doing business for life sciences companies. WhizAI lowers total cost of ownership (TCO) while making data insights more accessible to business users. Traditionally, data analytics TCO has been a significant expense for life sciences organizations.
Transforming Life Sciences Commercial Function with AI and Augmented Analytics
In this whitepaper, sponsored by WhizAl, Everest Group explores the business case and profound impact Al and Augmented Analytics can have on the life sciences commercial function across various use cases in Sales, Marketing, and Market Access. They examine what top pharma enterprises are looking for in an augmented analytics tool, a roadmap for how to get started, and a blueprint for adoption.
Augmented Analytics is “On the Rise” on Gartner’s 2022 Hype Cycle for Life Science Commercial Operations
The Gartner® 2022 Hype Cycle™ for Life Science Commercial Operations introduces a new category, Augmented Analytics, this year. WhizAI is listed as a sample vendor in the Augmented Analytics category in this Hype Cycle. This summary report covers the following highlights.
Why Domain Expertise Is Essential for Life Science Analytics
Domain expertise matters. Consider this: Enterprises choose transportation and logistics companies that have created the specific types of services they need. Businesses seek professional services with experience in their industries and look for consultants with good track records in their markets. However, remember that domain expertise benefits extend to analytics platforms, particularly those deployed for life sciences.